US20020106791A1 - Beta taipoxin as a cell growth factor and method - Google Patents
Beta taipoxin as a cell growth factor and method Download PDFInfo
- Publication number
- US20020106791A1 US20020106791A1 US10/004,085 US408501A US2002106791A1 US 20020106791 A1 US20020106791 A1 US 20020106791A1 US 408501 A US408501 A US 408501A US 2002106791 A1 US2002106791 A1 US 2002106791A1
- Authority
- US
- United States
- Prior art keywords
- cell growth
- growth factor
- culture medium
- taipoxin
- ile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 6
- 230000010261 cell growth Effects 0.000 title abstract description 51
- 239000003102 growth factor Substances 0.000 title description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 239000006143 cell culture medium Substances 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 11
- 241000237297 Stenopus scutellatus Species 0.000 claims description 8
- 239000003998 snake venom Substances 0.000 claims description 4
- 241000272104 Oxyuranus scutellatus scutellatus Species 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 12
- 208000027418 Wounds and injury Diseases 0.000 abstract description 12
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000002435 venom Substances 0.000 description 14
- 231100000611 venom Toxicity 0.000 description 14
- 210000001048 venom Anatomy 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 230000002297 mitogenic effect Effects 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 241000272102 Oxyuranus Species 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007952 growth promoter Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 1
- 101150096839 Fcmr gene Proteins 0.000 description 1
- SAEBUDRWKUXLOM-ACZMJKKPSA-N Glu-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O SAEBUDRWKUXLOM-ACZMJKKPSA-N 0.000 description 1
- YRMZCZIRHYCNHX-RYUDHWBXSA-N Glu-Phe-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O YRMZCZIRHYCNHX-RYUDHWBXSA-N 0.000 description 1
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 1
- WWEWGPOLIJXGNX-XUXIUFHCSA-N Lys-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N WWEWGPOLIJXGNX-XUXIUFHCSA-N 0.000 description 1
- 101000911775 Mus musculus Hsc70-interacting protein Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 241000272112 Oxyuranus scutellatus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229940099261 silvadene Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Definitions
- the present invention relates to the discovery of non-toxic beta taipoxin as a cell growth factor and a potent mitogen from poisonous snake venom.
- Said composition consists of a polypeptide of beta taipoxin having molecular weight approximately 14,000 daltons and is free of toxic effects.
- Taipoxin as a whole intact molecule isolated from the venom of the Australian taipan Oxyuranus s. scutellatus is the most lethal neurotoxin.
- the whole molecule of taipoxin is a complex, composed of three subunits designated as alpha, beta and gamma, having molecular weight 45,6000 daltons.
- Taipoxin can not be isolated by ion-xchange chromatography, since ion exchangers tend to dissociate the active toxin complex.
- the major lethality of taipoxin is due to the very basic alpha subunit.
- the molecular weights of alpha, beta and gamma subunits of taipoxin are 13,750, 13,473 and 18,354 daltons respectively.
- EGF epidermal growth factor
- FGF fibroblast growth factor
- OGF nerve growth factor
- PDGF platelet derived growth factor
- the beta taipoxin as a cell growth factor can be used to grow cells in serum free medium. Routinely, cells are grown in the presence of 5 to 20% fetal bovine serum (FBS) for research or production. The purification of products derived from cells grown in serum containing medium is a cumbersome task and furthermore, fetal bovine serum is the most expensive ingredient of the medium A mitogen like cell growth factor will provide serum free environment with adequate cell proliferation.
- FBS fetal bovine serum
- a further object of this invention is to provide non-toxic beta taipoxin having mitogenic activity as a composition for the promotion of rapid burn and wound healing. In the case of cuts, surgical incisions, and abrasions to lessen the risk of infection and to shorten recovery time.
- Cell growth factor has been isolated as the beta subunit of taipoxin by fractionating Oxyuranus s. scutellatus snake venom by high pressure liquid chromatography. After testing for mitogenic activity in all fractions, the mitogenic activity was revealed in one of the fractions.
- Cell growth factor is a beta taipoxin; which is a non-toxic fraction of snake venom and is a potent mitogen.
- Cell growth factor has been isolated from the venom of the poisonous snake species Oxyuranus s. scutellatus.
- the concentration of 0.1 ⁇ g/ml of the beta taipoxin non-toxic subunit becomes a cell growth factor and in serum free medium it gives growth equivalent to medium containing 10% serum for a wide range of cells.
- Cell growth factor is a beta taipoxin peptide having a molecular weight 14,000 daltons.
- beta taipoxin as a cell growth factor acts as a potent mitogen.
- the cut portion of mouse hip skin healed much faster when cell growth factor was applied as compared to the control counter part.
- Cell growth factor helped heal a chronic foot wound of a friend.
- Cell growth factor is claimed as wound healer and its use may be extended to treat burns.
- FIG. 1 is a high pressure liquid chromatography profile of Oxyuranus s. scutellatus venom, resolved into 11 major fractions. Peak number 6 is representative of beta taipoxin.
- FIG. 2 is a high pressure liquid chromatography profile of concentrated fraction number 6 containing beta taipoxin.
- FIG. 3 is an electrophoresis profile of beta taipoxin on a 14% Novex gel, showing the molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14 % precast gel.
- Lanes 1 and 2 contain the cell growth factor, lane 3 contains the markers.
- the cell growth factor consists essentially of a peptide of which first 15 amino acid sequence is: Asp-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn, which is exactly similar to beta taipoxin. For convenience this sequence is referred herein as SEQ ID No: 1. It is believed that any peptide having the partial amino acid sequence SEQ ID No: 1 exhibits substantial utility as a cell growth promoter, a potent mitogen, regardless whether it is synthesized or derived from natural sources.
- cell growth factor we mean a substance whose presence produces a substantial nmitogenic effect on various types of cells, and that the mitogenic effect is indicated, by an increase in cell growth or by a decreased duplication time of various types of cells.
- the peptide cell growth factor contains the first fifteen amino acids at N-terminal as given by SEQ ID No: 1, and has a molecular weight of about 14,000 daltons revealed by electrophoresis which is similar to beta taipoxin.
- cell growth factor is water soluble and stable at 4 ° C. storage for its biological activity.
- Cell growth factor is stable at room temperature, 74 ° C. for several weeks and its biological mitogenic activity is not altered by exposing it to ultra violet light overnight.
- Cell growth factor beta taipoxin
- Cell growth factor may be obtained essentially as a fraction of venom, from species of poisonous snake.
- Cell growth factor is preferably obtained from the venom of a species of Australian taipan snake, particularly the species Oxyuranus s. scutellatus.
- the active cell growth factor a non-toxic beta taipoxin is preferably separated from fresh frozen venom, although lyophilized whole venom may also be used.
- the liquid venom is diluted 1:1 with 0,01 M phosphate buffer saline (PBS) and preferably centrifuged to sediment insoluble debris, which can also be removed by filtration.
- PBS phosphate buffer saline
- the diluted and centrifuged 50 mg venom is loaded on high pressure liquid chromatography, from Toso Co. Japan and the ion exchange column from Polymer Laboratories UK, maintained at 20 ° C. temperature.
- a plurality of fractions according to the relative ionic charge are eluted preferably, using gradient Tnzma(2-amino-2-(hydroxymethyl)propane-1,3-diol)-HCl buffer pH 7.3.
- the Toso high pressure liquid chromatography automatically mixes 1.0 molar Triztna-HCL buffer with water to yield gradient Trizma-HCl buffer from 0.01 molar to 1.0 molar. Any suitable gradient buffer may be used and Trizma-HCl buffer having pH 6.0 to 8.0 can be used.
- Fraction 6 represents the active cell growth factor of beta taipoxin.
- the fraction containing the mitogenic active peptide may be used in this form as a cell growth promoter, but may also be and preferably is further purified to obtain 100% purity to substantially remove mitogenic inactive substances as well.
- the mitogenic active fraction 6 is concentrated and dialyzed simultaneously using dialysis apparatus from Spectrum Co., to 1/20 volume and further purified by high pressure liquid chromatography as second run under identical conditions, such as gradient buffer temperature etc.
- the second time running of the concentrate of the cell growth factor fraction 6 resolved into one peak (Drawing No. 2). This peak material is sequenced for its first fifteen amino acids from the N-terminal SEQ ID No:
- each fraction was tested for the cell proliferative activity on rat adrenal pheochromocytoma, PC12, cells in concentrations ranging from 5 ⁇ g/ml to 0.1 ⁇ g/ml.
- PC12 cells were maintained in Dulbecco Modified Eagle's Medium (DMEM) serum free medium and various concentrations of 11 fractions were added.
- DMEM Dulbecco Modified Eagle's Medium
- the growth pattern of PC12 cells in presence of each fraction was compared to the cells maintained in DMEM containing 10% serum. All fractions showed toxic effect when the concentration of the fraction was greater than 1 ⁇ g/ml.
- fraction 6 of Oxyuranus S. scutellatus venom showed proliferative growth of PC12 cells at 1, 0.5 and 0.1 ⁇ g/ml concentration.
- cell growth factor can be a wound healer.
- Cell growth factor is stable at 4° C. for a long period of time.
- Cell growth factor is non-toxic, when 50 ⁇ g in 0.5 ml is injected intraperitoneally in a 20 gram mouse. Being a cell growth promoter having a neurotrophic activity, this cell growth factor will be an excellent wound and burn healer.
- the cell growth factor is beta taipoxin of the present invention is a particularly effective mitogenic agent. Since it is substantially free of toxic activity, the cell growth factor can be used to grow wide range of cells in the serum free medium. Further, it may be used for a rapid proliferation of cells either for research or for production purposes, also in the case of dermal monolayers to grow in vitro for the treatment of bum victims and for wound healing.
- cell growth factor which is a beta taipoxin
- its method of preparation of the present invention has utility for treating bums and wounds including chronic wounds.
- the healing effects is accomplished by treating the wounds or cuts with cell growth factor having 100 ⁇ g/ml protein concentration in PBS in liquid form. It can be used after mixing with silvadene or any other appropriate ointment.
- no scar is produced because the hard dead tissue on the wound sloughs off as a effect of cell growth factor.
- the concentrated fraction number 6 which was obtained by initial fractionating the crude venom, resolved into a single peak on second time fractionation on high pressure liquid chromatography under identical conditions.
- the peak material was estimated to have a molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14% precast gel (Drawing No. 3).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn is used in a cell culture medium to promote cell growth in vitro and in the treatment of wounds. A method of preparation of the peptide is also claimed.
Description
- This application is a division of application Ser. No. 08/237,129, filed May 3, 1994, now the disclosure of which is incorporated by reference, and a division of application Ser. No. 08/657,164, filed Jun. 3, 1996, now , the disclosure of which is incorporated by reference..
- The present invention relates to the discovery of non-toxic beta taipoxin as a cell growth factor and a potent mitogen from poisonous snake venom. Said composition consists of a polypeptide of beta taipoxin having molecular weight approximately 14,000 daltons and is free of toxic effects.
- Taipoxin as a whole intact molecule isolated from the venom of the Australian taipan Oxyuranus s. scutellatus is the most lethal neurotoxin. The whole molecule of taipoxin is a complex, composed of three subunits designated as alpha, beta and gamma, having molecular weight 45,6000 daltons.
- Taipoxin can not be isolated by ion-xchange chromatography, since ion exchangers tend to dissociate the active toxin complex. The major lethality of taipoxin is due to the very basic alpha subunit. The molecular weights of alpha, beta and gamma subunits of taipoxin are 13,750, 13,473 and 18,354 daltons respectively.
- To date numerous growth factors have been isolated from various sources, and have been characterized To name a few, epidermal growth factor (EGF), fibroblast growth factor (FGF), nerve growth factor OGF) and platelet derived growth factor (PDGF).
- It is an object of this invention that the beta taipoxin as a cell growth factor can be used to grow cells in serum free medium. Routinely, cells are grown in the presence of 5 to 20% fetal bovine serum (FBS) for research or production. The purification of products derived from cells grown in serum containing medium is a cumbersome task and furthermore, fetal bovine serum is the most expensive ingredient of the medium A mitogen like cell growth factor will provide serum free environment with adequate cell proliferation.
- A further object of this invention is to provide non-toxic beta taipoxin having mitogenic activity as a composition for the promotion of rapid burn and wound healing. In the case of cuts, surgical incisions, and abrasions to lessen the risk of infection and to shorten recovery time.
- Cell growth factor has been isolated as the beta subunit of taipoxin by fractionating Oxyuranus s. scutellatus snake venom by high pressure liquid chromatography. After testing for mitogenic activity in all fractions, the mitogenic activity was revealed in one of the fractions. Cell growth factor is a beta taipoxin; which is a non-toxic fraction of snake venom and is a potent mitogen. Cell growth factor has been isolated from the venom of the poisonous snake species Oxyuranus s. scutellatus.
- The concentration of 0.1 μg/ml of the beta taipoxin non-toxic subunit becomes a cell growth factor and in serum free medium it gives growth equivalent to medium containing 10% serum for a wide range of cells. Cell growth factor is a beta taipoxin peptide having a molecular weight 14,000 daltons. In vivo experiments proved that beta taipoxin as a cell growth factor acts as a potent mitogen. The cut portion of mouse hip skin healed much faster when cell growth factor was applied as compared to the control counter part. Cell growth factor helped heal a chronic foot wound of a friend. Cell growth factor is claimed as wound healer and its use may be extended to treat burns.
- FIG. 1 is a high pressure liquid chromatography profile of Oxyuranus s. scutellatus venom, resolved into 11 major fractions.
Peak number 6 is representative of beta taipoxin. - FIG. 2 is a high pressure liquid chromatography profile of concentrated
fraction number 6 containing beta taipoxin. - FIG. 3 is an electrophoresis profile of beta taipoxin on a 14% Novex gel, showing the molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14 % precast gel.
1 and 2 contain the cell growth factor,Lanes lane 3 contains the markers. - The cell growth factor consists essentially of a peptide of which first 15 amino acid sequence is: Asp-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn, which is exactly similar to beta taipoxin. For convenience this sequence is referred herein as SEQ ID No: 1. It is believed that any peptide having the partial amino acid sequence SEQ ID No: 1 exhibits substantial utility as a cell growth promoter, a potent mitogen, regardless whether it is synthesized or derived from natural sources. By the term, cell growth factor, we mean a substance whose presence produces a substantial nmitogenic effect on various types of cells, and that the mitogenic effect is indicated, by an increase in cell growth or by a decreased duplication time of various types of cells.
- Preferably, the peptide cell growth factor contains the first fifteen amino acids at N-terminal as given by SEQ ID No: 1, and has a molecular weight of about 14,000 daltons revealed by electrophoresis which is similar to beta taipoxin. In addition, cell growth factor is water soluble and stable at 4 ° C. storage for its biological activity. Cell growth factor is stable at room temperature, 74 ° C. for several weeks and its biological mitogenic activity is not altered by exposing it to ultra violet light overnight.
- Cell growth factor, beta taipoxin, may be obtained essentially as a fraction of venom, from species of poisonous snake. Cell growth factor is preferably obtained from the venom of a species of Australian taipan snake, particularly the species Oxyuranus s. scutellatus.
- The non-toxic beta taipoxin which is an active cell growth factor is obtained by separating the peptide fraction by, high pressure liquid chromatography, using ion exchange chromatography.
- The active cell growth factor, a non-toxic beta taipoxin is preferably separated from fresh frozen venom, although lyophilized whole venom may also be used. The liquid venom is diluted 1:1 with 0,01 M phosphate buffer saline (PBS) and preferably centrifuged to sediment insoluble debris, which can also be removed by filtration. Typically, the diluted and centrifuged 50 mg venom is loaded on high pressure liquid chromatography, from Toso Co. Japan and the ion exchange column from Polymer Laboratories UK, maintained at 20 ° C. temperature. A plurality of fractions according to the relative ionic charge are eluted preferably, using gradient Tnzma(2-amino-2-(hydroxymethyl)propane-1,3-diol)-HCl buffer pH 7.3. The Toso high pressure liquid chromatography automatically mixes 1.0 molar Triztna-HCL buffer with water to yield gradient Trizma-HCl buffer from 0.01 molar to 1.0 molar. Any suitable gradient buffer may be used and Trizma-HCl buffer having pH 6.0 to 8.0 can be used.
- The venom of Oxyuranus s. scutellatus resolved into 11 major fractions by high pressure liquid chromatography (Drawing No. 1).
Fraction 6 represents the active cell growth factor of beta taipoxin. The fraction containing the mitogenic active peptide may be used in this form as a cell growth promoter, but may also be and preferably is further purified to obtain 100% purity to substantially remove mitogenic inactive substances as well. Preferably, the mitogenicactive fraction 6 is concentrated and dialyzed simultaneously using dialysis apparatus from Spectrum Co., to 1/20 volume and further purified by high pressure liquid chromatography as second run under identical conditions, such as gradient buffer temperature etc. The second time running of the concentrate of the cellgrowth factor fraction 6 resolved into one peak (Drawing No. 2). This peak material is sequenced for its first fifteen amino acids from the N-terminal SEQ ID No: - 1 and was found to be exactly similar to beta taipoxin.
- Initially each fraction was tested for the cell proliferative activity on rat adrenal pheochromocytoma, PC12, cells in concentrations ranging from 5 μg/ml to 0.1 μg/ml. PC12 cells were maintained in Dulbecco Modified Eagle's Medium (DMEM) serum free medium and various concentrations of 11 fractions were added. The growth pattern of PC12 cells in presence of each fraction was compared to the cells maintained in DMEM containing 10% serum. All fractions showed toxic effect when the concentration of the fraction was greater than 1 μg/ml. However,
fraction 6 of Oxyuranus S. scutellatus venom showed proliferative growth of PC12 cells at 1, 0.5 and 0.1 μg/ml concentration. - The proliferative of cell growth factor was studied on wide range of cells of primary and secondary cultures. The results on primary cell cultures are shown in table 1.
TABLE 1 Growth stimulating effect of cell growth factor on primary cultures of mouse kidney and spleen cells versus conventional medium containing 10% FBS and serum free medium Mouse Kidney Mouse Spleen Medium 48 hours 96 hours 48 hours 96 hours 10% FBS ++ ++++ − ++ no FBS − + − − no FBS + 0.5 μg/ml +++ ++++ ++ ++ CGF no FBS + ++ ++++ ++ ++ 0.1 μg/ml CGF -
TABLE 2 Growth stimulating effect of cell growth factor on PC12 Cells* Incubation period Medium 48 hours 96 hours 10% FBS 2.3 × 105 4.3 × 105 Serum free 1.0 × 105 0.6 × 105 serum free + toxic toxic 5 μg/ml CGF serum free + 1.9 × 105 2.1 × 105 1 μg/ml CGF serum free + 2.3 × 105 4.0 × 105 0.5 μg/ml CGF serum free + 2.4 × 105 4.3 × 105 0.1 μg/ml CGF -
TABLE 3 Growth stimulating effect of cell growth factor on various established cell lines Serum free medium Cell Line none 0.1 μg/ml 0.5 μg/ ml 10% FBS Chang's liver retarded normal normal normal NIH 3T3 retarded normal normal normal Skin no growth normal normal normal NS-20 retarded normal normal normal PC-12 retarded neurite neurite normal SP/2 no growth no growth no growth normal - The results show that cell growth factor is nitogenic for most of the cells tested. Cell growth factor seems to be neurotrophic as PC12 cells show neurite outgrowth in the presence of this growth factor.
- Experimental cuts were made on both hips of test mnice. The right cuts were treated with cell growth factor and the left with PBS. The cuts treated with cell growth factor healed much faster.
- A friend, experienced a deep wound on the top of his foot, which showed non closure after 3 months and was deemed to be chronic. After applying cell growth factor, twice a day, his wound began to heal. He experienced the effect of cell growth factor within 24 hours.
- Therefore, cell growth factor can be a wound healer.
- Cell growth factor is stable at 4° C. for a long period of time. Cell growth factor is non-toxic, when 50 μg in 0.5 ml is injected intraperitoneally in a 20 gram mouse. Being a cell growth promoter having a neurotrophic activity, this cell growth factor will be an excellent wound and burn healer.
- The cell growth factor is beta taipoxin of the present invention is a particularly effective mitogenic agent. Since it is substantially free of toxic activity, the cell growth factor can be used to grow wide range of cells in the serum free medium. Further, it may be used for a rapid proliferation of cells either for research or for production purposes, also in the case of dermal monolayers to grow in vitro for the treatment of bum victims and for wound healing.
- It is further believed that cell growth factor, which is a beta taipoxin, and its method of preparation of the present invention has utility for treating bums and wounds including chronic wounds. Generally, the healing effects is accomplished by treating the wounds or cuts with cell growth factor having 100 μg/ml protein concentration in PBS in liquid form. It can be used after mixing with silvadene or any other appropriate ointment. The application of cell growth factor once or twice a day on the afflicted area, followed by dressing with silvadeen, the healing effect starts within 24 hours. Moreover, after the wound is healed, no scar is produced because the hard dead tissue on the wound sloughs off as a effect of cell growth factor.
- The
concentrated fraction number 6 which was obtained by initial fractionating the crude venom, resolved into a single peak on second time fractionation on high pressure liquid chromatography under identical conditions. The peak material was estimated to have a molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14% precast gel (Drawing No. 3). - The forgoing description of the invention is illustrative and explanatory thereof, and many variations will occur to those in the art. It is intended that all such variations within the scope and spirit of the appended claims be embraced thereby.
-
1 1 1 15 PRT OXYURANUS SCUTELLATUS ISOLATE FROM VENOM 1 Asp Leu Val Glu Phe Gly Lys Met Ile Glu Cys Ala Ile Arg Asn 5 10 15
Claims (7)
1. A culture medium characterized by the presence of a peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn identified in SEQ ID No: 1.
2. A culture medium as in claim 1 further characterized in that the peptide comprises beta taipoxin obtained from snake venom.
3. A culture medium as in claim 2 further characterized in that the beta taipoxin is obtained from the species Oxyuranus s. scutellatus, an Australian taipan snake.
4. A culture medium as in claim 3 , further characterized by the absence of serum.
5. A culture medium as in claim 4 further characterized in that the beta taipoxin has a molecular weight of about 14,000 daltons and is present at a concentration in the range of from about 0.1 μg/ml to about 1 μg/ml.
6. A method for cultivating various types of eukaryotic cells, said method comprising providing a cell culture medium;
placing cells in the cell culture medium; and
cultivating said cells,
characterized in that the cell culture medium contains a peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn identified in SEQ ID No: 1.
7. A method as in claim 6 is further characterized in that the cell culture medium is serum free and the peptide comprises beta taipoxin at a concentration in the range of 0.1 μg/ml to 1 μg/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/004,085 US20020106791A1 (en) | 1994-05-03 | 2001-10-23 | Beta taipoxin as a cell growth factor and method |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/237,129 US6316602B1 (en) | 1994-05-03 | 1994-05-03 | Beta taipoxin as a cell growth factor and method |
| US08/657,164 US6307031B1 (en) | 1994-05-03 | 1996-06-03 | Beta taipoxin as a cell growth factor and method |
| US10/004,085 US20020106791A1 (en) | 1994-05-03 | 2001-10-23 | Beta taipoxin as a cell growth factor and method |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/237,129 Division US6316602B1 (en) | 1994-05-03 | 1994-05-03 | Beta taipoxin as a cell growth factor and method |
| US08/657,164 Division US6307031B1 (en) | 1994-05-03 | 1996-06-03 | Beta taipoxin as a cell growth factor and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020106791A1 true US20020106791A1 (en) | 2002-08-08 |
Family
ID=22892454
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/237,129 Expired - Fee Related US6316602B1 (en) | 1994-05-03 | 1994-05-03 | Beta taipoxin as a cell growth factor and method |
| US08/657,164 Expired - Fee Related US6307031B1 (en) | 1994-05-03 | 1996-06-03 | Beta taipoxin as a cell growth factor and method |
| US10/004,085 Abandoned US20020106791A1 (en) | 1994-05-03 | 2001-10-23 | Beta taipoxin as a cell growth factor and method |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/237,129 Expired - Fee Related US6316602B1 (en) | 1994-05-03 | 1994-05-03 | Beta taipoxin as a cell growth factor and method |
| US08/657,164 Expired - Fee Related US6307031B1 (en) | 1994-05-03 | 1996-06-03 | Beta taipoxin as a cell growth factor and method |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6316602B1 (en) |
| EP (1) | EP0759069B1 (en) |
| AU (1) | AU691621B2 (en) |
| CA (1) | CA2189357A1 (en) |
| DE (1) | DE69525450T2 (en) |
| WO (1) | WO1995029987A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002061044A2 (en) * | 2001-01-30 | 2002-08-08 | Lipps Binie V | Synthetic peptide and uses for same |
| WO2003072543A2 (en) * | 2002-02-21 | 2003-09-04 | Quark Biotech, Inc. | Methods of preventing or treating brain ischemia or brain injury |
| US20060034823A1 (en) * | 2004-08-13 | 2006-02-16 | Paul Reid | Method of production and use of crotoxin as an analgesic |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443546A (en) * | 1980-07-07 | 1984-04-17 | The Beth Israel Hospital Association | Process and composition for propagating mammalian cells |
| US4341762A (en) * | 1981-04-07 | 1982-07-27 | Haast William E | Use of snake venoms for treatment of neurological and related disorders |
| US4741902A (en) * | 1986-07-14 | 1988-05-03 | Haast William E | Compositions for treatment of neurological and related disorders |
-
1994
- 1994-05-03 US US08/237,129 patent/US6316602B1/en not_active Expired - Fee Related
-
1995
- 1995-05-03 DE DE69525450T patent/DE69525450T2/en not_active Expired - Fee Related
- 1995-05-03 EP EP95921232A patent/EP0759069B1/en not_active Expired - Lifetime
- 1995-05-03 AU AU26360/95A patent/AU691621B2/en not_active Ceased
- 1995-05-03 CA CA 2189357 patent/CA2189357A1/en not_active Abandoned
- 1995-05-03 WO PCT/US1995/005657 patent/WO1995029987A1/en not_active Ceased
-
1996
- 1996-06-03 US US08/657,164 patent/US6307031B1/en not_active Expired - Fee Related
-
2001
- 2001-10-23 US US10/004,085 patent/US20020106791A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995029987A1 (en) | 1995-11-09 |
| AU2636095A (en) | 1995-11-29 |
| DE69525450D1 (en) | 2002-03-21 |
| CA2189357A1 (en) | 1995-11-09 |
| EP0759069A4 (en) | 1998-06-10 |
| EP0759069A1 (en) | 1997-02-26 |
| US6307031B1 (en) | 2001-10-23 |
| US6316602B1 (en) | 2001-11-13 |
| AU691621B2 (en) | 1998-05-21 |
| EP0759069B1 (en) | 2002-02-13 |
| DE69525450T2 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thomas et al. | Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity | |
| Postlethwaite et al. | Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. | |
| Erlanson et al. | Purification and characterization of two proteins with co-lipase activity from porcine pancreas | |
| CA1300010C (en) | Hepatocyte growth factor | |
| Seyedin et al. | Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. | |
| EP0419534B1 (en) | Wound healing | |
| Nissley et al. | Multiplication-stimulating activity (MSA): A somatomedin-like polypeptide from cultured rat liver cells | |
| JPS6136223A (en) | Polypeptide cartilage inductive factor in bone | |
| HOFMANN et al. | The seminal vesicle of the bull: a new and very rich source of nerve growth factor | |
| GB2146335A (en) | Wound healing compositions | |
| Abe et al. | Purification of rabbit tumor necrosis factor | |
| US5104977A (en) | Purified transforming growth factor beta | |
| Adlakha et al. | Partial purification and characterization of mitotic factors from HeLa cells | |
| Asashima et al. | The vegetalizing factor from chicken embryos: its EDF (activin A)-like activity | |
| US5070188A (en) | Acylated epidermal growth factor | |
| Tokuyama et al. | Bovine colostric transforming growth factor-β-like peptide that induces growth inhibition and changes in morphology of human osteogenic sarcoma cells (MG-63) | |
| US20020106791A1 (en) | Beta taipoxin as a cell growth factor and method | |
| Tokuyama et al. | Purification and identification of TGF-β2-related growth factor from bovine colostrum | |
| RU2136695C1 (en) | Serum glycoprotein showing biological activity at superlow doses | |
| Cai et al. | Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum | |
| KR920002163B1 (en) | Psoriasis treatment with tgf-beta | |
| EP0655251B1 (en) | Pharmaceutical composition for preventing or treating bone fractures | |
| Li et al. | Mechanical and humoral factors in wound healing | |
| US5545720A (en) | Protein PHBP-70 | |
| Agrez et al. | A fibroblast elongation factor purified from colon carcinoma cells shares sequence identity with TIMP-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |